Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Oosterwijk

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Breast Cancer Research : BCR|February 10, 2009
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family historyEncarna B Gómez García, Jan C Oosterwijk, Maarten Timmermans, et al.
The Lancet. Oncology|June 22, 2019
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trialSepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, et al.
JAMA Oncology|July 31, 2020
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial RiskH Amarens Geuzinge, Inge-Marie Obdeijn, Emiel J T Rutgers, et al.
Human Mutation|May 10, 2006
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic settingAnnemarie H van der Hout, Ans M W van den Ouweland, Rob B van der Luijt, et al.
Journal of Medical Genetics|May 12, 2017
The <i>BRCA1</i> c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortiumSetareh Moghadasi, Huong D Meeks, Maaike Pg Vreeswijk, et al.
Journal of Medical Genetics|June 4, 2024
Validation of the BOADICEA model in a prospective cohort of <i>BRCA1/2</i> pathogenic variant carriersXin Yang, Thea M Mooij, Goska Leslie, et al.
JNCI Cancer Spectrum|March 16, 2019
The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With <i>BRCA1</i> or <i>BRCA2</i> MutationsMary Beth Terry, Yuyan Liao, Karin Kast, et al.
British Journal of Cancer|January 5, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
Genome Medicine|May 18, 2022
Breast cancer risks associated with missense variants in breast cancer susceptibility genesLeila Dorling, Sara Carvalho, Jamie Allen, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Breast Cancer Research : BCR|February 10, 2009
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family historyEncarna B Gómez García, Jan C Oosterwijk, Maarten Timmermans, et al.
The Lancet. Oncology|June 22, 2019
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trialSepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, et al.
JAMA Oncology|July 31, 2020
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial RiskH Amarens Geuzinge, Inge-Marie Obdeijn, Emiel J T Rutgers, et al.
Human Mutation|May 10, 2006
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic settingAnnemarie H van der Hout, Ans M W van den Ouweland, Rob B van der Luijt, et al.
Journal of Medical Genetics|May 12, 2017
The <i>BRCA1</i> c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortiumSetareh Moghadasi, Huong D Meeks, Maaike Pg Vreeswijk, et al.
Journal of Medical Genetics|June 4, 2024
Validation of the BOADICEA model in a prospective cohort of <i>BRCA1/2</i> pathogenic variant carriersXin Yang, Thea M Mooij, Goska Leslie, et al.
JNCI Cancer Spectrum|March 16, 2019
The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With <i>BRCA1</i> or <i>BRCA2</i> MutationsMary Beth Terry, Yuyan Liao, Karin Kast, et al.
British Journal of Cancer|January 5, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
Genome Medicine|May 18, 2022
Breast cancer risks associated with missense variants in breast cancer susceptibility genesLeila Dorling, Sara Carvalho, Jamie Allen, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
Pageof 10